Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.

Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis.
复制标题

DOI:
10.18632/oncotarget.3366
复制
发表时间:
2015-03-20
期刊:
影响因子:
--
通讯作者:
Wang J
Wang J
中科院分区:
其他
文献类型:
--
作者:
Zhang L;Shao L;Creighton CJ;Zhang Y;Xin L;Ittmann M;Wang J

文献摘要

参考文献

被引文献

相似文献

大多数前列腺癌(Pca)患者携带TMPRSS2/ERG(T/E)融合基因,人们对T/E融合如何促进前列腺癌的进展产生了极大的兴趣。我们发现T/E融合可以通过增加核因子-kB p65Ser536(P536)的磷酸化来激活核因子-kB途径,但p536在前列腺癌中的作用从未被研究过。我们在这里报道了活性p536可以显著增加细胞活力和转化PNT1a细胞(一种永生化的正常细胞系),这表明p536在促进前列腺癌的发生中起着关键作用。我们已经发现了一组p536调控基因,其中我们验证了p536对CCL2的调控。根据所有证据,我们支持T/E融合、NF-kB p536和CCL2形成一个信号链。最后,PNT1a细胞(不致瘤)在激活的AKT存在的情况下,当野生型或活性p65过表达时,可以在SCID小鼠中形成肿瘤,证明了NF-kB和AKT信号在促进PCa发生中的协同活性。这些结果表明,针对T/E融合、NF-kB、CCL2和/或AKT通路的联合治疗可能对T/E融合基因表达的PCa有效。如果成功,这种靶向治疗将使一半以上接受T/E融合的PCA患者受益。
Majority of prostate cancer (PCa) patients carry TMPRSS2/ERG (T/E) fusion genes and there has been tremendous interest in understanding how the T/E fusion may promote progression of PCa. We showed that T/E fusion can activate NF-kB pathway by increasing phosphorylation of NF-kB p65 Ser536 (p536), but the function of p536 has never been studied in PCa. We report here that active p536 can significantly increase cell motility and transform PNT1a cells (an immortalized normal cell line), suggesting p536 plays a critical role in promoting PCa tumorigenesis. We have discovered a set of p536 regulated genes, among which we validated the regulation of CCL2 by p536. Based on all evidence, we favor that T/E fusion, NF-kB p536 and CCL2 form a signaling chain. Finally, PNT1a cells (not tumorigenic) can form tumors in SCID mice when overexpressing of either wild type or active p65 in the presence of activated AKT, demonstrating synergistic activities of NF-kB and AKT signals in promoting PCa tumorigenesis. These findings indicate that combination therapies targeting T/E fusion, NF-kB, CCL2 and/or AKT pathways may have efficacy in T/E fusion gene expressing PCa. If successful, such targeted therapy will benefit more than half of PCa patients who carry T/E fusions.
DOI: 10.1158/1940-6207.capr-11-0077
发表时间: 2011-09
期刊: Cancer prevention research (Philadelphia, Pa.)
影响因子: --
作者:
Li Y;Kong D;Wang Z;Ahmad A;Bao B;Padhye S;Sarkar FH
通讯作者: Sarkar FH
DOI: 10.1038/nature03491
发表时间: 2005-04-28
期刊: NATURE
影响因子: 64.8
作者:
Lawrence, T;Bebien, M;Karin, M
通讯作者: Karin, M
DOI: 10.1593/neo.07307
发表时间: 2007-07-01
期刊: NEOPLASIA
影响因子: 4.8
作者:
Loberg, Robert D.;Ying, Chi;Pienta, Kenneth J.
通讯作者: Pienta, Kenneth J.
DOI: 10.1074/jbc.m113.539965
发表时间: 2014-04-25
影响因子: 4.8
作者:
Li, Xueling;Zhao, Yingxin;Kudlicki, Andrzej
通讯作者: Kudlicki, Andrzej
DOI: 10.1093/carcin/bgh198
发表时间: 2004-10-01
期刊: CARCINOGENESIS
影响因子: 4.7
作者:
Hu, J;Nakano, H;Colburn, NH
通讯作者: Colburn, NH